脂类和与儿科喘和喘风险因素的相互关系
Yulu Chen1, Antonio Checa2,3, Pei Zhang2,4
1Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Allergy
|November 28, 2023
概括
儿童喘风险与脂相关,但机制尚不清楚. 这项研究发现,特定的脂子类与喘及其风险因素有差异性关联,这表明有针对性的干预措施.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 不调节的脂代谢与儿童喘风险有关.
- 具体的脂类及其在喘中的机制仍然不太清楚.
- 由于与已确定的风险因素的相互作用,喘的发展是复杂的.
研究的目的:
- 为了研究脂和儿童喘之间的复杂关系.
- 阐明特定的脂子类在喘发病过程中的作用.
- 为了检查脂蛋白如何与已知的喘风险因素相互作用.
主要方法:
- 从使用LC-MS/MS的997名儿童的血中量化77种脂.
- 分析了与喘,肺功能和风险因素 (ORMDL3 SNPs,维生素D,肠道微生物群) 的关联.
- 在两个独立的队列 (VDAART,COPSAC2010) 中利用了对种族差异的分析.
主要成果:
- 在患有喘和风险因素的儿童中观察到高脂水平.
- 特定的脂类表现出差异性关联:循环/代谢代谢物与喘和肺功能相关,而胺与风险因素相关,但与喘直接无关.
- 胺被确定为喘发展的风险因素的调解者和相互作用者.
结论:
- 斯芬戈脂类子类在喘及其危险因素中发挥着独特的作用.
- 虽然整体脂升可能是有害的,但脂与喘风险因素的增加特别相关.
- 向喘风险因素可能会调节脂平衡,可能会影响喘的发展.
相关概念视频
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management
411
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
411
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
Antiasthma Drugs: Leukotriene Modifiers
320
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
320


